- Conditions
- Heart Decompensation
- Interventions
- Nesiritide, Placebo
- Drug
- Lead sponsor
- Scios, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 171
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 168 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 991
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
- Interventions
- Spectris™ AD - Active, Spectris™ AD - Sham
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 68
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
- Conditions
- Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)
- Interventions
- Futibatinib
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
- Interventions
- Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2036
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more
- Conditions
- Asthma
- Interventions
- Tezepelumab, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 13 Years to 81 Years
- Enrollment
- 951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 52
- States / cities
- Dothan, Alabama • Gilbert, Arizona • Bakersfield, California + 45 more
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma
- Interventions
- Anastrozole, Exemestane, Laboratory Biomarker Analysis, Letrozole, Quality-of-Life Assessment, Systemic Chemotherapy, Tamoxifen Citrate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1435
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Interventions
- V941, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Placebo, DT120
- Other · Drug
- Lead sponsor
- Definium Therapeutics US, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 27 more
- Conditions
- Head and Neck Neoplasms, Mucositis
- Interventions
- Brilacidin, Placebo
- Drug · Other
- Lead sponsor
- Innovation Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
- Conditions
- Pancreatic Cancer
- Interventions
- BPM31510 Nanosuspension Injection, Gemcitabine
- Drug
- Lead sponsor
- BPGbio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Gilroy, California + 6 more
- Conditions
- Psychosis Associated With Alzheimer's Disease
- Interventions
- KarXT
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 148
- States / cities
- Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more
- Conditions
- Covid19
- Interventions
- Placebo, Montelukast
- Other · Drug
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 109
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 96 more
- Conditions
- Peripheral Arterial Occlusive Disease
- Interventions
- PAD endovascular treatments
- Other
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 52
- States / cities
- Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 47 more
- Conditions
- Advanced Cancer
- Interventions
- FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
- Interventions
- Casdatifan, Cabozantinib, Placebo
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Filgotinib, Placebo to match filgotinib
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 72
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
- Conditions
- Esophageal Cancer
- Interventions
- Nivolumab, Docetaxel/Paclitaxel
- Drug
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 7
- States / cities
- Gilbert, Arizona • Washington D.C., District of Columbia • Orlando, Florida + 4 more
- Conditions
- Soft Tissue Lesion
- Interventions
- PEF ablation
- Device
- Lead sponsor
- Galvanize Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Rancho Mirage, California • Naples, Florida + 8 more
- Conditions
- Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
- Interventions
- TRL1068 (calpurbatug), a human monoclonal antibody, DAIR
- Drug · Procedure
- Lead sponsor
- Trellis Bioscience LLC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 11
- States / cities
- Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 8 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Deucravacitinib, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 33
- States / cities
- Gilbert, Arizona • Jonesboro, Arkansas • Fontana, California + 30 more
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- Tiespectus, Aflibercept
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 60
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Encino, California + 56 more
- Conditions
- Essential Thrombocythemia
- Interventions
- INCA033989, Best Available Treatment
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 37 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 565 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Fremont, California + 30 more